CNBX Pharmaceuticals Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CNBX Pharmaceuticals Inc. (CNBX: OTCQB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel cannabinoid-based products and technologies for cancer treatment; its lead candidates include Cannabics SR, an oral capsule for patients with advanced cancer and cancer anorexia cachexia syndrome, RCC-33, a proprietary cannabinoid formulation as the first antitumor drug candidate for colorectal cancer, PLP-33 for lateral spreading or sessile colorectal polyps, BRST-33 for breast cancer, MLN-33 for melanoma, PRST-33 for prostate cancer, and Cannabics CDx, an ex-vivo drug sensitivity test. Founded in 2004 as Thrust Energy Corp. and transitioning to biotechnology in 2014 with a name change to Cannabics Pharmaceuticals Inc. in 2014 and further to CNBX Pharmaceuticals Inc. in March 2022, the company is headquartered in Bethesda, Maryland, with research and development conducted in a government-licensed facility in Israel. It operates in the oncology segment targeting personalized anti-cancer therapies using high-throughput screening and bioinformatics for cannabinoid formulations addressing colorectal cancer, breast cancer, prostate cancer, melanoma, and related conditions such as cachexia. Recent developments include a strategic focus on advancing RCC-33 and Cannabics SR toward Phase I/II(a) clinical trials planned for 2026 pending financing, a significant reduction in operating expenses and research activities in fiscal 2025 to conserve resources amid funding needs met through convertible loans totaling $160,000 in the year ended August 31, 2025, preparation for a Pre-IND meeting with the US FDA, and contingency plans for collaborations with medical centers or acquisition of additional programs in high-unmet-need areas.
CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX) Short Interest Update
Short Interest in CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX) Drops By 97.5%
CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021
Cannabics Pharmaceuticals Announces Two New Provisional Patents: Compositions and Methods For Treating Cancer
Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer
Cannabics Announces New Corporate Logo, New Website and New Company Presentation
Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston
Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases
Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine
World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors
Cannabics Pharmaceuticals Appoints a Second Independent Board Member
Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member
Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice
Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases
Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program
The European Patent Office Grants Cannabics Pharmaceuticals Patent for Company's Personalized Medicine Drug Discovery Technology
Cannabics Pharmaceuticals Files a PCT Patent Application for Proprietary Cancer Treatment Formulations
Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer